ATE227586T1 - Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein - Google Patents

Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein

Info

Publication number
ATE227586T1
ATE227586T1 AT96926748T AT96926748T ATE227586T1 AT E227586 T1 ATE227586 T1 AT E227586T1 AT 96926748 T AT96926748 T AT 96926748T AT 96926748 T AT96926748 T AT 96926748T AT E227586 T1 ATE227586 T1 AT E227586T1
Authority
AT
Austria
Prior art keywords
lag
lymphocytes
detection
cells
methods
Prior art date
Application number
AT96926748T
Other languages
English (en)
Inventor
Sergio Romagnani
Original Assignee
Applied Research Systems
Inst Nat Sante Rech Med
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Inst Nat Sante Rech Med, Roussy Inst Gustave filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE227586T1 publication Critical patent/ATE227586T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
AT96926748T 1995-07-21 1996-07-19 Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein ATE227586T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US136795P 1995-07-21 1995-07-21
US268395P 1995-09-21 1995-09-21
PCT/US1996/011994 WO1997003695A1 (en) 1995-07-21 1996-07-19 Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein

Publications (1)

Publication Number Publication Date
ATE227586T1 true ATE227586T1 (de) 2002-11-15

Family

ID=26668940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926748T ATE227586T1 (de) 1995-07-21 1996-07-19 Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein

Country Status (12)

Country Link
US (1) US6197524B1 (de)
EP (1) EP0843557B1 (de)
JP (2) JP2000508226A (de)
AT (1) ATE227586T1 (de)
AU (1) AU701375B2 (de)
CA (1) CA2227334A1 (de)
DE (1) DE69624824T2 (de)
DK (1) DK0843557T3 (de)
ES (1) ES2186797T3 (de)
IL (1) IL122832A (de)
PT (1) PT843557E (de)
WO (1) WO1997003695A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1373099A (en) * 1997-11-13 1999-06-07 Napolitano, Monica Th2 cell depletion; compositions; methods
ATE519779T1 (de) * 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
WO2004078928A2 (en) * 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
EP1987839A1 (de) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Zytotoxischer monoklonaler Anti-LAG-3-Antikörper und seine Verwendung bei der Behandlung und Vorbeugung von Organtransplantatabstoßung und Autoimmunerkrankungen
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8481308B2 (en) * 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
HRP20201113T1 (hr) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
US20150231077A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
TWI777174B (zh) * 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
AU2018219909B2 (en) 2017-02-10 2025-02-27 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
EP3969040A1 (de) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Kombination von pd-1-inhibitoren und lag-3-inhibitoren zur erhöhung der wirksamkeit bei der behandlung von krebs
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20250155054A (ko) 2023-03-13 2025-10-29 리제너론 파마슈티칼스 인코포레이티드 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
WO1995030750A2 (fr) * 1994-05-06 1995-11-16 Institut Gustave Roussy Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype

Also Published As

Publication number Publication date
ES2186797T3 (es) 2003-05-16
EP0843557A4 (de) 1999-04-14
DK0843557T3 (da) 2003-03-10
DE69624824T2 (de) 2003-09-11
IL122832A (en) 2006-08-20
AU6678496A (en) 1997-02-18
DE69624824D1 (de) 2002-12-19
IL122832A0 (en) 1998-08-16
US6197524B1 (en) 2001-03-06
JP2000508226A (ja) 2000-07-04
JP2008150362A (ja) 2008-07-03
PT843557E (pt) 2003-03-31
CA2227334A1 (en) 1997-02-06
EP0843557B1 (de) 2002-11-13
EP0843557A1 (de) 1998-05-27
AU701375B2 (en) 1999-01-28
WO1997003695A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
ATE227586T1 (de) Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein
Thiel et al. Immunomagnetic cell sorting—pushing the limits
Povoleri et al. Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa
Majewska et al. Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis
Prussin Cytokine flow cytometry: understanding cytokine biology at the single-cell level
Sizemore et al. Phylogeny of lymphocyte heterogeneity: the cellular requirements for in vitro mitogenic responses of channel catfish leukocytes.
US9360480B2 (en) Assay method for peptide specific T-cells
DE69422604D1 (de) Vorrichtung und Verfahren, die Bioaffinitätsassay und elektrophoretische Auftrennung kombinieren
ATE251304T1 (de) Verfahren und zusammensetzungen zur beobachtung der zellulären verarbeitung von beta-amyloid- vorläuferproteinen
WO1996023060B1 (en) Method for isolating dendritic cells
DE69333289D1 (de) Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
CN101743470A (zh) 共聚物测定
Barberá et al. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients
WO1999036568A3 (de) Verfahren zum identifizieren von t-zell-stimulierenden proteinfragmenten
Gomes et al. Leishmania braziliensis amastigotes stimulate production of IL‐1β, IL‐6, IL‐10 and TGF‐β by peripheral blood mononuclear cells from nonendemic area healthy residents
Sharp et al. Detection of basal levels and induction of delta opioid receptor mRNA in murine splenocytes
Darcissac et al. Selective induction of CD11a, b, c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides
Le et al. Production of soluble HLA‐class‐I molecules by IFN‐γ‐induced colon‐adenocarcinoma cells
US5395751A (en) Assay for cytotoxic T cells
Halminen et al. Interferon‐γ Production in Antigen Specific T Cell Response: Quantitation of Specific mRNA and Secreted Protein
JPH10505905A (ja) 免疫細胞の増殖性老化の診断試験
ATE352785T1 (de) Verfahren zum nachweis von hepatitis c antigenen
US20210371821A1 (en) Induced regulatory t cells, methods of production, and uses thereof
Jayasinghe et al. Single cell resolution analysis of multi-tissue derived human iNKT cells reveals novel transcriptional paradigms

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0843557

Country of ref document: EP

EEIH Change in the person of patent owner